CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
PF-07321332/ritonavir +4 moredrug
Likely dose
Not stated in record
Key inclusion· 3
  • ✓Overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and standard 12-lead ECGs
  • ✓BMI 17.5-30.5 kg/m² and total body weight >50 kg
  • ✓Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and study procedures
Key exclusion· 8
  • ✕Positive test for SARS-CoV-2 infection at screening or Day -1
  • ✕Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease
  • ✕Clinically relevant cardiac abnormalities including acute myocardial infarction, unstable ischemic conditions, ventricular dysfunction, serious arrhythmias, prolonged PR interval, cardiomyopathy, heart failure, structural heart disease, or Wolff Parkinson-White syndrome
  • ✕Any condition affecting drug absorption such as gastrectomy or cholecystectomy

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05263895
NCT05263895Phase 1Completed
CompareCT.gov

A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF PF-07321332 FOLLOWING ORAL ADMINISTRATION OF 4 DIFFERENT FORMULATIONS RELATIVE TO THE COMMERCIAL TABLET FORMULATION IN HEALTHY ADULT PARTICIPANTS UNDER FASTED CONDITIONS

Pfizer·interventional·Posted Mar 3, 2022·Updated Jun 11, 2025

In Brief

A Phase 1 clinical trial evaluating PF-07321332/ritonavir and PF-07321332 for Bioavailability. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this study is to estimate the relative bioavailability of PF-07321332 in different formulations in healthy adult participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBioavailability
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedMar 3, 2022
Enrollment StartMar 3, 2022
Primary CompletionMay 16, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.3 years ago

Interventions

PF-07321332/ritonavirdrug

PF-07321332 ritonavir will be administered as single dose orally

PF-07321332/ritonavirdrug

PF-07321332 ritonavir will be administered as single oral dose orally.

PF-07321332/ritonavirdrug

PF-07321332 ritonavir will be administered as single oral dose orally.

PF-07321332/ritonavirdrug

PF-07321332 ritonavir will be administered as single oral dose orally.

PF-07321332drug

PF-07321332 will be administered as single oral dose orally.